SYSTEMATIC REVIEW

REVISED Post-stroke fatigue: a scoping review [version 2; peer review: 2 approved]

Ghazaleh Aali ^{1,2}, Avril Drummond³, Roshan das Nair ^{1,2},
Farhad Shokraneh ^{1,2,4}

¹Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK

²Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK

³Faculty of Medicine and Health Sciences, School of Health Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK

⁴King's Technology Evaluation Centre (KITEC), London Institute of Healthcare Engineering, School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

V2 First published: 07 Apr 2020, 9:242
<https://doi.org/10.12688/f1000research.22880.1>
 Latest published: 25 Aug 2020, 9:242
<https://doi.org/10.12688/f1000research.22880.2>

Abstract

Background: Post-stroke fatigue (PSF) is one of the most common and frustrating outcomes of stroke. It has a high prevalence and it can persist for many years after stroke. PSF itself contributes to a wider range of undesirable outcomes that affect all aspects of daily life. The aim of this review was to identify and summarise the most recent research on PSF, in order to update the evidence base.

Methods: We updated an existing review (Hinkle *et al.* 2017) systematically searching CINAHL, MEDLINE, PsycINFO, and PubMed to cover new research studies between 1st March 2016 and the search date (19th January 2020). We included interventional and observational research, and clinical practice guidelines that were not covered in the original review. After duplicate removal in EndNote, two reviewers screened the search results in Rayyan, and data from eligible full texts were extracted onto an Excel spreadsheet. Finally, we used RobotReviewer and a human reviewer to assess the risk of bias of randomised trials for this scoping review.

Results: We identified 45 records for 30 studies (14 observational, 10 interventional studies, and 6 guidelines). Apart from one, the interventional studies were single-centred, had high risk of bias and small sample size (median 50). They investigated exercise, pharmacotherapy, psychotherapy, education, and light therapy. Observational studies mainly reported the factors related to PSF including co-morbidities, depression and anxiety, quality of life, activities of daily living, stroke severity, medication use and polypharmacy, polymorphism, pain, apathy, limb heaviness, neuroticism, mobility, and thyroid-stimulating hormone. Guidelines either did not report on PSF or, when reported, their recommendations were supported by little or low level of evidence.

Conclusion: Although we identified a number of recent studies which

Open Peer Review

Approval Status

	1	2
version 2		
(revision)		
25 Aug 2020	view	
version 1		
07 Apr 2020	view	view

1. **Carina U. Persson**, University of Gothenburg, Gothenburg, Sweden

2. **Nicola Hancock** , University of East Anglia, Norwich, UK

Any reports and responses or comments on the article can be found at the end of the article.

have added to our current knowledge on PSF, none are robust enough to change current clinical practice.

Keywords

Post-Stroke Fatigue, Scoping Review

Corresponding author: Ghazaleh Aali (Ghazaleh.Aali@nottingham.ac.uk)

Author roles: **Aali G:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Drummond A:** Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing; **das Nair R:** Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing; **Shokraneh F:** Conceptualization, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Drummond A, Thomas S, Jones F, dasNair R, Sprigg N, Jones A. Nottingham Fatigue Study-Developing a Fatigue Programme: NotFAST2. Stroke Association. Research ID: SA PG 19\100060; 20 Months (1st Dec 2019 – 31st July 2021). URL: <https://www.stroke.org.uk/research/notfast2-nottingham-fatigue-study-developing-fatigue-intervention> This scoping review reports independent research funded by the UK Stroke Association. The views expressed are those of the author(s) and not necessarily those of the UK Stroke Association.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Aali G *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Aali G, Drummond A, das Nair R and Shokraneh F. **Post-stroke fatigue: a scoping review [version 2; peer review: 2 approved]** F1000Research 2020, 9:242 <https://doi.org/10.12688/f1000research.22880.2>

First published: 07 Apr 2020, 9:242 <https://doi.org/10.12688/f1000research.22880.1>

REVISED Amendments from Version 1

In Table 2, we replaced the red and green colour keys with grey and white.

In Table 4, we added the effect sizes for interventional studies as reported in the original studies.

In the Discussion, we added the need for future research to include sensitivity analysis and the need for international standard reporting guidelines for measuring and reporting the outcomes. We suggested that future reviews should consider the impact of research on online delivery of interventions.

We changed 'Limitations' to 'Limitations and strengths' and added three strengths of the current scoping review.

Any further responses from the reviewers can be found at the end of the article

Introduction

Post-stroke fatigue (PSF) has been defined as 'overwhelming feeling of exhaustion or tiredness', which is unrelated to exertion, and does not typically improve with rest¹. It is one of the most common outcomes of stroke and its prevalence varies between 25% and 85%; however, it is generally accepted that it affects 50% of people after stroke². PSF is linked to undesirable stroke outcomes and affects patients' participation in studies, adherence to medication, and effectiveness of rehabilitation³. This has a negative impact on patients' quality of life and daily life activities^{4–7}, and also contributes to the burden on family members and carers⁸.

Although researchers have attempted to explain PSF mechanisms⁹, its aetiology still remains unclear. This is partly because there are many contributing factors to PSF^{8,10–32}, and each research team may focus only on some of the factors to find a route for preventing, treating or managing PSF. Any endeavour to find the most effective intervention in the research literature leads to a collection of heterogeneous interventions from physiotherapy³³ and exercise^{34–38} to psychotherapy, pharmacotherapy, and recently laser therapy^{39–41}.

As a systematic effort to review these scattered interventions, a Cochrane review^{42,43} compared all the tested PSF treatments to a control group, to standard care, or to each other, through reviewing randomised controlled trials (RCTs). This review concluded that there was insufficient evidence of the efficacy of the tested interventions in trials, and more robust research with adequate sample sizes was required^{42,43}. Since then, more recent systematic reviews until 2019 have attempted to summarise the evidence of effectiveness of Modafinil, mindfulness training, a traditional Chinese medicine, and smart technologies, but still came to a similar conclusion to that of the Cochrane review in 2015^{44–47}.

As a result of such uncertainty, current clinical practice guidelines rely on low levels of evidence, such as expert consensus, to make recommendations for PSF^{48,49}. However, the efforts to design and test treatments continue, which makes it

necessary to keep up-to-date with new research and practice literature.

Objective

The objective of this review was to identify and summarise the most recent research literature related to PSF in order to update the evidence base. As there was an existing review covering the literature up until 2016⁵⁰, we only updated the literature not covered in this review.

Methods

Methods from an existing review

In 2017, Hinkle *et al.*⁵⁰ published a review covering emerging evidence relating to the management of PSF, up to and including February 2016. Because of the comprehensiveness of this review, we only searched for literature published after 1st March 2016. As the search methods of the Hinkle *et al.* review were not reproducible, and the search strategies and results were not available, we contacted the corresponding author and their librarian on 15th October 2019. Since we did not receive a reply, we designed the search methods for the reported databases in order to capture the majority of the literature included in Hinkle *et al.*'s review.

Scoping review methods

We followed Arksey and O'Malley framework⁵¹ for conducting this scoping review. We also used Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Extension for Scoping Reviews (PRISMA-ScR) for reporting⁵². The relevant PRISMA-ScR checklist is available as *Extended data* and the flow diagram is reported in the Results section (Figure 1).

Search methods

We ran a search to include studies in the English language only, between 1st March 2016 and 19th January 2020 (search date) in CINAHL via EBSCOhost, MEDLINE via Ovid SP, PubMed (excluding MEDLINE), and PsycINFO via Ovid. There were no limitations to document type (e.g. thesis), study completion status (e.g. ongoing), and publication status (e.g. unpublished) at the search stage. We report the search strategies for all databases in *Extended data*.

Selection of studies

We imported the search results into EndNote X6 and de-duplicated them based on title, and additionally double-checked the automatically identified duplicates manually. Two reviewers (GA and FS) screened the results independently against the eligibility criteria using Rayyan, which is a recommended screening system⁵³. Discrepancies were resolved through discussions or asking a third reviewer (AD).

Two reviewers (GA and FS) also investigated the full texts of relevant search results against the same criteria involving a third reviewer (AD) in case of disagreement. At full text screening stage, we also investigated the reference lists of the

Figure 1. PRISMA flow diagram.

relevant studies to identify additional relevant studies. Since one study may have multiple reports or publications, we kept a record and cited all the reports of a single study to provide a better overview of the new research evidence.

Eligibility criteria

We included the following studies:

- Studies of adult humans with PSF – any definition of PSF – at any stage of the stroke care continuum;
- Any interventional (clinical trial) or observational (cohort, case-control, and cross-sectional) studies, and clinical practice guidelines;
- Studies reporting findings that had not been included in the previous review;
- Studies included in relevant systematic reviews.

We excluded the following studies:

- Studies with case reports, case series, and qualitative design;

- Studies included in Hinkle *et al.* or results which repeated the summarised knowledge in that review;
- Studies of pre-clinical nature;
- Clinical studies where fatigue was reported only as a side effect of the treatment;
- Studies focusing on single muscle fatigue or muscle fatigue in general;
- Studies not focusing on fatigue and/or stroke or focusing on heat stroke, athletes' fatigue or carers' fatigue;
- Systematic or narrative or review papers;
- Ongoing studies or protocols with no results (listed and cited in this paper for further follow-up);
- Tool validation studies without reporting new findings on PSF.

Data extraction methods

One reviewer (GA) extracted and entered the data in Excel 2007 and the second reviewer (FS) checked the extracted and

entered data against the full text and, if appropriate, corrected or amended the data.

For interventional studies, we extracted PICOS (participants, intervention, comparison, outcomes, and study design) and other data points:

- Study name and year;
- Clinical trial registration number (for further check on selective reporting bias);
- Country of origin;
- Number of centres;
- Patients: Number of patients, type of stroke, time passed after stroke;
- Intervention and controls: name of intervention and duration;
- Primary and secondary outcomes measures in general and fatigue measures in particular, outcome endpoints, and main findings related to PSF;
- Study design (single-arm clinical trial (CT), controlled clinical trial (CCT), or RCT);

For observational studies, we extracted:

- Study name and year;
- Clinical trial registration number (for further check on selective reporting bias);
- Country of origin;
- Number of centres;
- Patients: Number of patients, type of stroke, time passed after stroke;
- Primary and secondary outcomes measures in general and fatigue measures in particular, outcome endpoints, and main findings related to PSF;
- Study design (cohort, case-control, or cross-sectional).

For clinical practice guidelines, we extracted the following data:

- Study name and year;
- Country and organisation who produced the guideline;
- Recommendations on PSF;
- Evidence base reporting the level of evidence or study designs related to the level of evidence.

Quality assessment methods

We used RobotReviewer for assessing the risk of bias in the four categories of the Cochrane Risk of Bias tool⁵⁴ for included RCTs. Although this automation system is reliable for checking the risk of bias for certain bias categories^{55,56}, one of the reviewers (GA) also double-checked and revised RobotReviewer's assessment and corrected the data where necessary. We also added a 'selective reporting of outcomes' category to the list of biases to cover the main biases in Cochrane Risk of Bias

tool. Because of 'scoping' nature of this review and lack of time and resources, we did not assess the risk of bias for non-RCTs.

Synthesis methods

We summarised the data from the new relevant literature in tables. We did not proceed to a meta-analysis for fatigue outcomes due to the heterogeneity of studies. We checked if any of the interventional studies considered following the CONSORT⁵⁷ for reporting RCTs or TIDieR checklist⁵⁸ to report the components of new interventions.

Results

The search identified 1021 results. After screening, we included 45 relevant records related to 24 studies and 6 guidelines (Figure 1).

The characteristics of included interventional studies have been charted in Table 1. The table shows eight RCTs some with multiple reports and one with a follow-up study⁵⁹⁻⁷³, one CCT⁷⁴, and two single-arm trials^{75,76}. All studies were based on single centre studies, except for West *et al.* (2019) which had two centres⁷¹. In studies that reported the intervention delivery details, the psychological interventions were delivered individually and face-to-face – rather than online – by psychologists. We also assessed the risk of bias for RCTs and reported the categories of risk in Table 2 with supporting statements in *Extended data*.

Most of the interventional studies have a medium to high risk of bias. Table 2 shows only two studies in white cells (indicating low risk of bias) but both have small sample size consisting of 34 (MIDAS study⁶³⁻⁶⁸) and 64 randomised patients⁶¹ respectively.

We identified 14 observational studies of which half had a prospective cohort design⁷⁷⁻⁹⁰ and the other half were cross-sectional surveys⁹¹⁻⁹⁷. Three cross-sectional surveys were embedded within cohort studies^{91,94,97}. Only one of the studies (NotFAST) had a follow-up report⁸¹⁻⁸⁵. Details of all studies are reported in Table 3 as well as the *Extended data*.

Table 4 summarises the main finding of each interventional study all of which either have high risk of bias or small sample size. Such limitations make it hard to transfer the research findings to practice.

The majority of observational studies investigated factors related to PSF including co-morbidities, physical and mental outcomes, illness characteristics, characteristics of interventions, and biomarkers (Table 5).

We identified six recent guidelines from three English-speaking countries including the UK⁴⁹ and two North American countries (one from Canada⁴⁸ and four from the USA⁹⁸⁻¹⁰¹). Among these, the Canadian guideline was the most recent and the only one with comprehensive recommendations

Table 1. Characteristics of included interventional studies.

Study name	Country	Design	No. of participants	Stroke type	Time after stroke	Interventions	Duration of intervention	Delivered by	Delivery mode
Chen <i>et al.</i> , 2016	Taiwan	RCT	41	With CHF	64.95±53.07 D	Inspiratory Muscle Training + TAU v. TAU	10 W (5 D/W)	Respiratory Therapist	NR
Chen <i>et al.</i> , 2019	Taiwan	RCT	72	Ischemic	NR	Mind-Body Exercise (Qigong) + TAU v. TAU	10 D	Researchers	Individual
Delva 2019	Ukraine	CCT	39	Ischemic/TIA	≥3 M	Acetylsalicylic Acid (Low Dose v. High Dose)	3 M	NR	NR
Liu <i>et al.</i> , 2016	Taiwan	RCT	64	Haemorrhagic /Infraction	≥3 M	Astragalus membranaceus v. Placebo	28 D	NR	NR
Liu <i>et al.</i> , 2018	China	RCT	140	NR	NR	Vitamin C v. Wuling	12 W	NR	NR
MIDAS	Australia	RCT Follow-Up	36 18/36	NR	≥3 M	Modafinil v. Placebo	6 W	Patients	Individual
Nguyen <i>et al.</i> , 2019	Australia	RCT	15	//	NR	CBT v. TAU	8 W	Psychologists*	Individual
Van Heest <i>et al.</i> , 2017	USA	1-Arm CT	49	NR	NR	Fatigue Management Course	6 W	Clinical Psychologist	Individual
West <i>et al.</i> , 2019	Denmark	RCT	90	NR	7.6±8.3 (Treatment), 6.0±4.4 (Control) D	Naturalistic Lighting (Artificial Sunlight Spectrum) v. Standard Indoor Lighting	45.3±22.1 (Treatment), 33.7±12.7 (Control) D	NA	Group
Wu <i>et al.</i> , 2017	UK	1-Arm CT	12	First/Recurrent	3±24 M	Manualised Psychological Intervention	7 S	Clinical Psychologist	Individual

* Psychologists with doctoral qualifications in clinical neuropsychology.

RCT: Randomised Controlled Trial; CCT: CONTROLLED CLINICAL TRIAL; CT: Clinical Trial; NR: Not Reported; NA: Not Applicable; CHF: Congestive Heart Failure; TIA: Transient Ischaemic Attack; D: Day; W: Week; M: Month; S: Session

Table 2. Risk of bias assessed by RobotReviewer and a human reviewer for randomised controlled trials.

Trial	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Selective reporting of outcomes
Chen <i>et al.</i> , 2016	?	?	?	+	+
Chen <i>et al.</i> , 2019	+	+	?	?	?
Delva 2019	?	?	?	?	?
Liu <i>et al.</i> , 2016	+	+	+	+	+
Liu <i>et al.</i> , 2018	?	?	?	?	?
MIDAS	+	+	+	+	+
Nguyen <i>et al.</i> , 2019	+	+	?	+	?
West <i>et al.</i> , 2019	+	+	?	?	+

Question marks in grey cells indicate unclear or high risk of bias and plus signs in white cells show low risk of bias.

Table 3. Characteristics of included observational studies.

Study name	Country	No. of centres	Design	No. of participants	Stroke type	Time after stroke**
ARCOS-IV	New Zealand	4	Cross-Sectional (in Cohort)	256/2096*	First, Ischemic, Haemorrhagic, Undetermined	4 Y
Blomgren <i>et al.</i> , 2019	Sweden	1	Cohort	296/411	First, Recurrent, Ischemic	7 Y
Chen <i>et al.</i> , 2018	USA	1	Cohort	128/203	Ischemic, Haemorrhagic	6 M
Choi-Kwon <i>et al.</i> , 2017a	South Korea	1	Cross-Sectional	373/469	Ischemic	3 M
Choi-Kwon <i>et al.</i> , 2017b	South Korea	1	Cohort	364/508	Ischemic	12 M
Douven <i>et al.</i> , 2017	Netherlands	2	Cohort	243/250	First, Ischemic	3, 6, 12 M
Kuppuswamy <i>et al.</i> , 2016	UK	3	Cross-Sectional	69	First	56.81±63 M
LAS-1	Sweden	1	Cross-Sectional (in Cohort)	349	NR	6 Y
Lau <i>et al.</i> , 2017	Hong Kong	1	Cross-Sectional	191	Ischemic	3 M
MacIntosh <i>et al.</i> , 2017	Canada	4	Cross-Sectional	335	Ischemic, Haemorrhagic	Within 6 M
NotFAST	UK	4	Cohort	268/371	First	4-6 W
			Follow-Up	263/371		6 M
STROKDEM	France	4	Cohort	153/179	Ischemic, Haemorrhagic	6 M
van Rijnsbergen <i>et al.</i> , 2019	Netherlands	1	Cross-Sectional (in Cohort)	208	First, Ischemic, Haemorrhagic, Recurrent	3.3±0.5 M
Wang <i>et al.</i> 2018	China	1	Cohort	634/703	Ischemic	Within 3 D

NR: Not Reported; Y: Year; M: Month; W: Week; D: Day

*For cohort studies, the left number shows the number of participants who finished follow-up, and the right number is the number of participants who started and took part in the study; for cross-sectional studies within cohort studies, the left number shows the number of participants in cross-sectional study and the right number is the number of participants in cohort study.

** Sometimes reported as time period and sometimes as mean and standard deviation across the studies.

Table 4. Descriptive summary of findings from included interventional studies.

Study Name	Fatigue measure	Endpoint	Main post-stroke fatigue finding*
Chen <i>et al.</i> , 2016	Secondary: FAS	W 10	There were no significant changes from baseline in FAS in either group (intervention: $p=0.218$; control: $p=0.475$; change between groups: $p=0.198$).
Chen <i>et al.</i> , 2019	Fatigue VAS	D 5, 10	Fatigue was not significantly associated with change in quality of life ($\beta = -0.21$, 95% CI $[-0.73; 0.31]$, $p=0.42$) and was not different in two groups.
Delva, 2019	FAS	D 3, M 1, 3	The use of aspirin in high dose during 3 months with PSF diagnosis within the first days post-stroke is associated with decreasing of fatigue intensity due to FAS and modifying of post-stroke inflammatory response ($p<0.05$).
Liu <i>et al.</i> , 2016	Primary: BFI	D28 $\pm$ 5, 84 $\pm$ 5	Astragalus membranaceus group had improved fatigue in visit 1–28 $\pm$ 5 days – post-therapy ($p=0.01$) and in follow-up in 84 $\pm$ 5 days post-therapy ($p=0.05$).
Liu <i>et al.</i> , 2018	Barthel Index	W 12	Wuling can inhibit the release rate of inflammatory factor, reduce the expression level of related inflammatory factors and improve PSF ($p<0.05$).
MIDAS	Primary: MFI	W 6, 7	Modafinil group reported decrease in fatigue ($\beta = -7.38$, 95% CI $[-21.76; -2.99]$, $p<0.001$) and improvement in quality of life ($\beta = 11.81$, 95% CI $[2.31; 21.31]$, $p=0.0148$).
		M 12	MFI and quality of life at baseline and their changes during treatment were correlated ($\beta = -1.975$, 95%CI $[-3.082; -0.869]$, $p < 0.001$). Five of the patients who continued taking daily modafinil demonstrated 33–38 point improvement in MFI compared to baseline.
Nguyen <i>et al.</i> , 2019	Primary: FSS	M 2, 4	CBT group demonstrated reduced fatigue relative to TAU post-therapy ($\beta = 1.74$, 95%CI $[0.70; 2.77]$, effect size (η^2)= .52) and two months post-therapy ($\beta = 1.92$, 95% CI $[0.24; 3.60]$, effect size (η^2)= .36).
Van Heest <i>et al.</i> , 2017	Primary: FACIT-Fatigue	W 6, 12	Participants showed reductions in fatigue at post-test ($p<0.001$; effect size (Cohen's d) = 21.19) and maintained it at follow-up ($p=0.315$; effect size (Cohen's d) = 0.23).
West <i>et al.</i> , 2019	Primary: MFI	Discharge	At discharge, patients from the naturalistic light group experienced less fatigue than the indoor light group (diff = -20.6% , 95% CI $[-35.0\%; -3.0\%]$, $p = 0.025$).
Wu <i>et al.</i> , 2017	Secondary: FAS	S 6, 1, M 3	Fatigue decreased post-treatment (mean difference=4.8, 95% CI $[-2.1; 11.6]$, $p = 0.15$), in one-month assessment (mean difference=7.0, 95% CI $[-0.8; 14.8]$, $p = 0.07$), and in three-month assessment (mean difference=9.3, 95% CI $[1.4; 17.1]$; $p = 0.03$).

FAS: Fatigue Assessment Scale; VAS: Visual Analogue Scale; BFI: Brief Fatigue Index; MFI: Multidimensional Fatigue Inventory; FSS: Fatigue Severity Scale; FACIT: Functional Assessment of Chronic Illness Therapy; W: Weeks; D: Day; M: Month; S: Session; TAU: Treatment As Usual; CBT: Cognitive Behavioural Therapy.

*Grey cells contain findings from low risk studies; however they have small sample size. We reported the data as reported in the original report.

on PSF. The UK guideline will be updated in 2021. Half of these guidelines, that is, all those from USA, have not provided specific recommendations on PSF, as reported in Table 6. In almost all the guidelines, the reliance on ‘experts’ consensus’ is apparent because of the limited evidence base for PSF (Table 6).

Discussion

We conducted this review to identify and summarise the most recent research studies on PSF since Hinkle *et al.*'s review (2017)⁵⁰. We therefore documented the interventional and observational research and clinical practice guidelines since March 2016. However, there were some key contributors to the weak evidence base: (i) recording and reporting only

some contributing factors to PSF in observational studies, (ii) the heterogeneity of designed interventions, (iii) high risk of bias, (iv) small sample size in interventional studies, and (v) variety of outcome measures in both observational and clinical studies. This, in turn, is reflected in the quality of the clinical recommendations for PSF.

Despite the high prevalence of PSF² and its obvious effects on treatment adherence¹⁰², in practice, only half of recent stroke guidelines have clinical recommendations on PSF. Of those that do, two guidelines provide only brief recommendations, and only one provides comprehensive recommendations, but these are based on low levels of evidence⁴⁸. The weak evidence base and the need to rely on expert consensus is

Table 5. Descriptive summary of findings from included observational studies.

Study name	Fatigue measure	Post-stroke fatigue finding
ARCOS-IV	FSS	Having hypertension, diabetes mellitus, and arrhythmia at the time of stroke were associated with increased PSF.
Blomgren <i>et al.</i> , 2019	FIS	Fatigue was independently explanatory of worse outcome on FAI summary score and domestic chores.
Chen <i>et al.</i> , 2018	FACIT-Fatigue	Early PSF appears to be largely attributable to stroke severity, while chronic fatigue occurs in the setting of medical co-morbidities and medication use.
Choi-Kwon <i>et al.</i> , 2017a	FSS	Of the 6 polymorphisms examined, only one marker, that is, low-activity Monoamine Oxidase A was associated with PSF in female patients.
Choi-Kwon <i>et al.</i> , 2017b	FSS	Musculoskeletal pain and central post-stroke pain was related to fatigue.
Douven <i>et al.</i> , 2017	FSS	No association between apathy and fatigue was found at baseline and no interaction with time was found. Change in fatigue from baseline to 12-month follow-up was associated with change in depression and with change in apathy. Bidirectional associations were found between PSF and PSD.
Kuppuswamy <i>et al.</i> , 2016	FSS	Those with high perceived limb heaviness also reported significantly higher levels of fatigue than those with no perceived limb heaviness, but there was no difference in weakness between the 2 groups.
LAS-1	FSS	In almost all Stroke Impact Scale domains the odds for PSF were higher in persons with a higher perceived impact. Fatigue is still present in one-third of persons six years after stroke onset.
Lau <i>et al.</i> 2017	FAS	Fatigue severity positively correlated with NEO Five-Factor Inventory neuroticism scores.
MacIntosh <i>et al.</i> , 2017	FAS	Fatigue and depressive symptoms are related distinctly to cognitive and mobility impairments post-stroke. Fatigue was associated with poorer lower limb motor function, and with cognition indirectly via depressive symptoms.
NotFAST	FSS of FAI	Pre-stroke fatigue, having a spouse/partner, lower Rivermead Mobility Index score, and higher scores on both the Brief Assessment Schedule Depression Cards and Beck Anxiety Index were independently associated with PSF. Of those reporting fatigue initially 69% continued to report fatigue in follow-up. New PSF cases were reported by 38%. Lower Nottingham Extended Activities of Daily Living scores and higher Beck Anxiety Index scores were independently associated with fatigue at six months.
STROKDEM	CFS	Medication use was not a PSF predictor; however, polypharmacy increased PSF severity.
van Rijsbergen <i>et al.</i> , 2019	FAS	Fatigue was associated with CLCE scores, independent of demographic, cognitive performance and stroke-related covariates. After including personality traits and coping styles in the model, independent associations with CLCE scores were found for fatigue and neuroticism.
Wang <i>et al.</i> , 2018	FSS	The serum levels of thyroid-stimulating hormone were inversely associated with the risk of PSF in both the acute phase and at follow-up. Thyroid function profiles may be predictor of PSF after acute ischemic stroke.

FSS: Fatigue Severity Scale; FIS: Fatigue Impact Scale; FACIT: Functional Assessment of Chronic Illness Therapy; FAS: Fatigue Assessment Scale; FAI: Fatigue Assessment Inventory; PSD: Post-Stroke Depression; CFS: Chalder Fatigue Scale; CLCE: Checklist for Cognitive and Emotional consequences following stroke

likely to be the main reason that PSF is generally not covered in the guidelines.

The dominance of single-centred interventional studies with small sample sizes and interventions delivered within a 12-week period may be the reasons for absence of follow-up studies. MIDAS (interventional)^{63–65} and NotFAST (observational)^{81–85} are the only recent studies with novel and potentially long-term findings with larger sample size (in case of MIDAS 2)¹⁰³ or with the intention to design an intervention (NotFAST2)¹⁰⁴.

While the observational studies reported the type of stroke, the interventional studies did not include this important data, which makes it difficult to summarise studies. Most of participants entered the interventional studies three-months after stroke. This is likely to be due to a number of reasons; for example, fatigue is not recognised immediately after a stroke, some studies want to ensure that participants have a continuous fatigue, and there is competition for recruitment in the early stages to more acute trials. However, one issue worth considering is whether the construct of PSF holds for fatigue experienced in research

Table 6. Descriptive summary of included clinical practice guidelines.

Citation	Country-Organisation	Recommendation	Evidence base
Braun <i>et al.</i> , 2016	USA-AHA/ASA	None	NR
Lancot <i>et al.</i> , 2019	Canada-CSBPR	See pages 15–16 of guideline.	RCT, CCT, CT, Consensus
NICE 2017	UK-NICE	Assess the person for mental and physical factors that may contribute to fatigue. Treat any reversible causes or exacerbating factors. Provide the person and their family/carers with information and help in anticipating and managing fatigue such as daily routines, modified tasks which balance activity and rest, planned exercise schedules, and sleep hygiene.	Cochrane SR, SR, Consensus
Peberdy <i>et al.</i> , 2017	USA-AHA	None	NR
VA-DoD 2019	USA-VA/DoD	None	NR
Winstein <i>et al.</i> , 2016	USA-AHA/ASA	An RCT compared a multi-component cognitive therapy + graded activity training versus cognitive therapy for 12 weeks and showed that the multi-component therapy is better than the cognitive therapy in reducing fatigue and improving physical endurance ... myths about exercise being unsafe, causing another stroke, or increasing fatigue should be dispelled during rehabilitation ... evidence is limited, many clinicians advise that for individuals who want to return to work, a tailored assessment of cognitive, perception, physical, and motor abilities can be performed to determine readiness and the needed accommodations to return to work based on individual's needs and capabilities for the specified job situation. The assessment may include executive functions, high-level oral and written communication, and fatigue. Once performance under the best conditions has been assessed, further assessment under conditions of fatigue and stress may be useful to mimic potential job situations.	RCT

AHA: American Heart Association; ASA: American Stroke Association; VA/DoD: Department of Veterans Affairs/Department of Defense; NICE: National Institute for Health and Care Excellence; CSBPR: Canadian Stroke Best Practice Recommendations by Management of Mood, Cognition and Fatigue Following Stroke Best Practice Writing Group/Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee/Canadian Stroke Consortium; NR: Not Reported; RCT: Randomised Controlled Trial; CCT: Controlled Clinical Trial; CT: Clinical Trial; SR: Systematic Review.

participants recruited years after their stroke, and whether this fatigue is a function of other issues. Future systematic reviews could address this issue by conducting sensitivity analyses comparing studies that include participants many years after their stroke with those including participants immediately after their stroke.

The variety of the interventions tested in studies and trials underlines the complexity of PSF and is an indication to researchers that future interventions will probably need to target multiple aspects of fatigue. While current reporting practice of interventions in RCTs included in our review is of concern (none followed TIDieR and two followed CONSORT), future studies should consider following reporting guidelines such as CONSORT and TIDieR for interventional studies, STROBE for observational studies, and RIGHT¹⁰⁵, AGREE¹⁰⁶, or CheckUP¹⁰⁷ for clinical practice guidelines. In addition, harmonisation of studies requires standard international guidelines regarding outcome measurements and time points for measuring PSF in a standard way to create a homogenous and collective body of evidence.

Among the observational studies, the population-based study from the stroke register in New Zealand⁹¹ and Sweden⁷⁷

provides valuable insights about the link between co-morbidities and increased PSF in long-term (4–7 years). This, and other similar register-based studies, represent the added value of having high-quality data in health system databases for long-term observational and register-based studies¹⁰⁸.

Psychologists delivered the psychotherapies in RCTs to individual patients and there was no intervention using online platforms as the media of delivery. This may be due to a number of reasons: it is usual to test the efficacy of an intervention face to face before moving to another medium; participants with stroke may have other problems which mean it is more difficult to deliver treatments online, e.g. communication issue and cognitive problems. Online delivery of such interventions is becoming more common in some clinical services, and new research is emerging¹⁰⁹. Therefore, future reviews may wish to consider the impact of such interventions delivered online.

Fatigue Severity Scale (FSS) was the main outcome measure for PSF in observational studies, whereas Fatigue Assessment Scale (FAS) was used more frequently than other measures in interventional studies. Bearing in mind that both these PSF measurement scales are valid and reliable, the

main reason that the FSS has been used more frequently is probably because it is now seen as a way to compare different studies: in simple terms, researchers use it because other researchers have used it. It is also relatively straight forward to complete.

Only one of the observational studies and half of the interventional studies were registered in clinical trial registers, with the remaining unregistered trials potentially introducing bias in selective reporting of outcomes^{110,111}. One of the interventional studies was registered retrospectively with potential for the same bias^{69,70}.

Limitations and strengths

It is possible that we overlooked studies that did not report PSF in the searchable part of the paper or if the report was not indexed in the searched databases. In such cases, we invite readers of this review to contact us or comment on the paper online.

Due to the challenges we faced in identifying the search strategies in the previous review when conducting this update, we have explicitly documented our search criteria and strategies so that this review can be easily repeated and updated by future researchers. We feel this is a key strength of this review. We also feel that the use of automation tools such as Rayyan and RobotReviewer for this evidence synthesis was a strength in terms of saving time and other resources while still maintaining the quality of the review. Finally involving a multi-disciplinary team of clinicians and methodologists (information specialist and systematic reviewer) allowed us to consider both the clinical and methodological aspects of the studies in this review.

Conclusion

The current trend of research on PSF shows the continued importance of this topic globally. Our review identified a weak evidence base that highlights the need for more research

that could have the following characteristics: I) studies to design and test multi-component interventions for PSF; and II) Robust RCTs with adequate sample sizes to produce the evidence for recommendations in guidelines. From our current knowledge on PSF, none of the recent studies are robust enough to change current clinical practice.

Data availability

Underlying data

Open Science Framework: Post-Stroke Fatigue: A Scoping Review, <https://doi.org/10.17605/OSF.IO/XJKCS>¹¹².

Registration DOI: <https://doi.org/10.17605/OSF.IO/XJKCS>

This project contains the following underlying data:

- Extracted data from included studies

Extended data

Open Science Framework: Post-Stroke Fatigue: A Scoping Review, <https://doi.org/10.17605/OSF.IO/XJKCS>¹¹².

This project contains the following extended data:

- Full search strategies
- Risk of bias assessment

Reporting guidelines

Open Science Framework: PRISMA-ScR checklist for 'Post-stroke fatigue: a scoping review', <https://doi.org/10.17605/OSF.IO/XJKCS>¹¹².

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Acknowledgments

We are grateful to Dr Fiona Nouri for her critical comments and proof-reading of the revised version of this paper before publication.

References

1. De Groot MH, Phillips SJ, Eskes GA: **Fatigue associated with stroke and other neurologic conditions: Implications for stroke rehabilitation.** *Arch Phys Med Rehabil.* 2003; **84**(11): 1714–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Cumming TB, Packer M, Kramer SF, et al.: **The prevalence of fatigue after stroke: A systematic review and meta-analysis.** *Int J Stroke.* 2016; **11**(9): 968–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. ACTRN12619000826145: **Too tired to recover: evaluation of a post-stroke fatigue management guideline.** 2019.
[Reference Source](#)
4. Lerdal A, Gay CL: **Acute-Phase Fatigue Predicts Limitations with Activities of Daily Living 18 Months after First-Ever Stroke.** *J Stroke Cerebrovasc Dis.* 2017; **26**(3): 523–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Ramírez-Moreno JM, Muñoz-Vega P, Alberca SB, et al.: **Health-Related Quality of Life and Fatigue After Transient Ischemic Attack and Minor Stroke.** *J Stroke Cerebrovasc Dis.* 2019; **28**(2): 276–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Toy G, Singer J, Balucani C, et al.: **Post Stroke Fatigue and Depression Predict Lower Health Related Quality of Life in Stroke Patients.** *Stroke.* (00392499). 2017; **48**: ATP153–ATP.
[Reference Source](#)
7. Broussy S, Saillour-Glenisson F, Garcia-Lorenzo B, et al.: **Sequelae and Quality of Life in Patients Living at Home 1 Year After a Stroke Managed in Stroke Units.** *Front Neurol.* 2019; **10**: 907.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Mandliya A, Das A, Unnikrishnan JP, et al.: **Post-stroke Fatigue is an Independent Predictor of Post-stroke Disability and Burden of Care: A Path analysis Study.** *Top Stroke Rehabil.* 2016; **23**(1): 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. De Doncker W, Dantzer R, Ormstad H, et al.: **Mechanisms of poststroke fatigue.** *J Neurol Neurosurg Psychiatry.* 2018; **89**(3): 287–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Paciaroni M, Acciarresi M: **Poststroke Fatigue.** *Stroke.* 2019; **50**(7): 1927–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Aarnes R, Stubberud J, Lerdal A: **A literature review of factors associated**

- with fatigue after stroke and a proposal for a framework for clinical utility. *Neuropsychol Rehabil.* 2019; 1–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Cumming TB, Yeo AB, Marquez J, *et al.*: Investigating post-stroke fatigue: An individual participant data meta-analysis. *J Psychosom Res.* 2018; 113: 107–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Delva II, Delva MY, Poltorapavlov VA: Clinical factors related to post-stroke fatigue within the first 3 month after acute cerebrovascular events. *Wiad Lek.* 2017; 70(3 pt 2): 581–5.
[PubMed Abstract](#)
 14. Delva II, Lytvynenko NV, Delva MY: Post-stroke fatigue and its dimensions within first 3 months after stroke. *Wiad Lek.* 2017; 70(1): 43–6.
[PubMed Abstract](#)
 15. Delva I: Factors associated with post-stroke fatigue dimensions over the second year after acute cerebrovascular events. *Bulletin of Problems Biology and Medicine.* 2018; 2(147): 139–42.
[Publisher Full Text](#)
 16. Delva I, Lytvynenko N, Delva M: Factors Associated with Post-Stroke Fatigue within the First 3 Month after Stroke. *Georgian Med News.* 2017; 6(267): 38–42.
[PubMed Abstract](#)
 17. Delva M, Lytvynenko N, Delva I: Factors Associated with Post-Stroke Fatigue during the Second Half Year after Stroke. *Georgian Med News.* 2017; 11(272): 59–64.
[PubMed Abstract](#)
 18. Delva M, Lytvynenko N, Delva I: Factors Associated with the Time-Based Phenomenology of Post-Stroke Fatigue over the First Year after Stroke Occurrence. *Georgian Med News.* 2018; 6(279): 92–7.
[PubMed Abstract](#)
 19. Delva MY, Delva II, Lytvynenko NV: Post-stroke fatigue and its dimensions over the second half year after stroke. *Wiad Lek.* 2018; 71(2 pt 2): 314–7.
[PubMed Abstract](#)
 20. Galligan NG, Hevey D, Coen RF, *et al.*: Clarifying the associations between anxiety, depression and fatigue following stroke. *J Health Psychol.* 2016; 21(12): 2863–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Goh HT, Stewart JC: Poststroke Fatigue Is Related to Motor and Cognitive Performance: A Secondary Analysis. *J Neurol Phys Ther.* 2019; 43(4): 233–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Graber M, Garnier L, Duloquin G, *et al.*: Association Between Fatigue and Cognitive Impairment at 6 Months in Patients With Ischemic Stroke Treated With Acute Revascularization Therapy. *Front Neurol.* 2019; 10: 931.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Holmqvist A, Berthold Lindstedt M, Möller MC: Relationship between fatigue after acquired brain injury and depression, injury localization and aetiology: an explorative study in a rehabilitation setting. *J Rehabil Med.* 2018; 50(8): 725–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Khan A, Delargy M: Post Stroke Fatigue; Point Prevalence, Characterization, Associations and Radiological Correlation in a Rehabilitation Hospital. *Ir Med J.* 2017; 110(10): 650.
[PubMed Abstract](#)
 25. Lagogianni C, Thomas S, Lincoln N: Examining the relationship between fatigue and cognition after stroke: A systematic review. *Neuropsychol Rehabil.* 2018; 28(1): 57–116.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Liu X: Fatigue and depression in Chinese stroke patients: A 1-year longitudinal study. *Dissertation Abstracts International: Section B: The Sciences and Engineering.* 2018; 79(1).
 27. Murphy S, Durand M, Negro F, *et al.*: The Relationship Between Blood Flow and Motor Unit Firing Rates in Response to Fatiguing Exercise Post-stroke. *Front Physiol.* 2019; 10: 545.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Mutai H, Furukawa T, Hourai A, *et al.*: Factors associated with multidimensional aspect of post-stroke fatigue in acute stroke period. *Asian J Psychiatr.* 2017; 26: 1–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Sarfo FS, Berchie P, Singh A, *et al.*: Prevalence, Trajectory, and Predictors of Poststroke Fatigue among Ghanaians. *J Stroke Cerebrovasc Dis.* 2019; 28(5): 1353–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Schow T, Teasdale TW, Quas KJ, *et al.*: Problems with balance and binocular visual dysfunction are associated with post-stroke fatigue. *Top Stroke Rehabil.* 2017; 24(1): 41–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Shepherd AI, Pulsford R, Poltawski L, *et al.*: Physical activity, sleep, and fatigue in community dwelling Stroke Survivors. *Sci Rep.* 2018; 8(1): 7900.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Sylva D, Sweeney A, Lendrem D, *et al.*: A scoping exercise to gauge the incidence of early post-stroke fatigue for patients at Newcastle community stroke services. *Int J Ther Rehabil.* 2017; 24(2): 52.
[Publisher Full Text](#)
 33. Alahmari W, Alhowimel A, Alotaibi M, *et al.*: Effectiveness of physiotherapy interventions for post stroke fatigue (PSF): a systematic review. *Physiotherapy.* 2019; 105(Suppl 1): e172.
[Publisher Full Text](#)
 34. Gbiri CAO, Olawale OA, Ogunmola OT: Task-oriented circuit training for post-stroke fatigue, sleep pattern, functional performance and societal re-integration in stroke survivors with post-stroke fatigue: a clinical controlled study. *International journal of stroke Conference: 11th world stroke congress, WSC 2018 Canada.* 2018; 13(2 Supplement 1): 86.
[Publisher Full Text](#)
 35. Durand MJ, Boerger TF, Nguyen JN, *et al.*: Two weeks of ischemic conditioning improves walking speed and reduces neuromuscular fatigability in chronic stroke survivors. *J Appl Physiol (1985).* 2019; 126(3): 755–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Durand MJ, Murphy SA, Schmit BD, *et al.*: Two Weeks of Ischemic Preconditioning Training on the Paretic Leg Improves Leg Strength and Delays Muscle Fatigue in Chronic Stroke. *Stroke.* 2017; 48: ATP150–ATP.
[Reference Source](#)
 37. Shahar N, Schwartz I, Portnoy S: Differences in muscle activity and fatigue of the upper limb between Task-Specific training and robot assisted training among individuals post stroke. *J Biomech.* 2019; 89: 28–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Vecchio M, Gracies JM, Panza F, *et al.*: Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: a Prospective Open-Label Observational Study. *J Stroke Cerebrovasc Dis.* 2017; 26(11): 2536–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. da Silva BP, Souza GADS, Filho AADN, *et al.*: Analysis of the effects of low-level laser therapy on muscle fatigue of the biceps brachii muscle of healthy individuals and spastic individuals: Study protocol for a single-center, randomized, double-blind, and controlled clinical trial. *Medicine (Baltimore).* 2019; 98(39): e17166.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. das Neves M, Reis M, Andrade E, *et al.*: Effects of low-level laser therapy (LLLT 808 nm) on lower limb spastic muscle activity in chronic stroke patients. *Lasers Med Sci.* 2016; 31(7): 1293–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. das Neves MF, Aleixo DC, Mendes IS, *et al.*: Long-term analyses of spastic muscle behavior in chronic poststroke patients after near-infrared low-level laser therapy (808 nm): a double-blinded placebo-controlled clinical trial. *Lasers Med Sci.* 2019.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Kennedy C, Kidd L: Interventions for post-stroke fatigue: A Cochrane review summary. *Int J Nurs Stud.* 2018; 85: 136–137.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Wu S, Kutlubaeve MA, Chun HY, *et al.*: Interventions for post-stroke fatigue. *Cochrane Database Syst Rev.* 2015; (7): CD007030.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Xu L, Xu XY, Hou XQ, *et al.*: Adjuvant therapy with *Astragalus membranaceus* for post-stroke fatigue: a systematic review. *Metab Brain Dis.* 2020; 35(1): 83–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Kettlewell J, das Nair R, Radford K: A systematic review of personal smart technologies used to improve outcomes in adults with acquired brain injuries. *Clin Rehabil.* 2019; 33(11): 1705–1712.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Ulrichsen KM, Kaufmann T, Dorum ES, *et al.*: Clinical Utility of Mindfulness Training in the Treatment of Fatigue After Stroke, Traumatic Brain Injury and Multiple Sclerosis: A Systematic Literature Review and Meta-analysis. *Front Psychol.* 2016; 7: 912.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Pacheco RL, Latorraca COC, da Silva LDGM, *et al.*: Modafinil for poststroke patients: A systematic review. *Int J Clin Pract.* 2019; 73(2): e13295.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Lancot KL, Lindsay MP, Smith EE, *et al.*: Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue following Stroke, 6th edition update 2019. *Int J Stroke.* 2019; InPress:InPress.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. National Institute for Health and Care Excellence. *Stroke and TIA.* 2017.
[Reference Source](#)
 50. Hinkle JL, Becker KJ, Kim JS, *et al.*: Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Stroke.* 2017; 48(7): e159–e170.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Arksey H, O'Malley L: Scoping studies: towards a methodological framework. *Int J Soc Res Methodol.* 2005; 8(1): 19–32.
[Publisher Full Text](#)
 52. Tricco AC, Lillie E, Zarin W, *et al.*: PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018; 169(7): 467–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Harrison H, Griffin SJ, Kuhn I, *et al.*: Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation. *BMC Med Res Methodol.* 2020; 20(1): 7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Higgins JPT, Altman DG: Assessing Risk of Bias in Included Studies. 2008; 187–241.
[Publisher Full Text](#)

55. Marshall IJ, Kuiper J, Wallace BC: **RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials.** *J Am Med Inform Assoc.* 2016; **23**(1): 193–201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Gates A, Vandermeer B, Hartling L: **Technology-assisted risk of bias assessment in systematic reviews: a prospective cross-sectional evaluation of the RobotReviewer machine learning tool.** *J Clin Epidemiol.* 2018; **96**: 54–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Schulz KF, Altman DG, Moher D, *et al.*: **CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.** *BMJ.* 2010; **340**: c332.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Hoffmann TC, Glasziou PP, Boutron I, *et al.*: **Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide.** *BMJ.* 2014; **348**: g1687.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Chen PC, Liaw MY, Wang LY, *et al.*: **Inspiratory muscle training in stroke patients with congestive heart failure: A CONSORT-compliant prospective randomized single-blind controlled trial.** *Medicine.* 2016; **95**(37): e4856.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Chen CH, Hung KS, Chung YC, *et al.*: **Mind-body interactive qigong improves physical and mental aspects of quality of life in inpatients with stroke: A randomized control study.** *Eur J Cardiovasc Nurs.* 2019; **18**(8): 658–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Liu CH, Tsai CH, Li TC, *et al.*: **Effects of the traditional Chinese herb *Astragalus membranaceus* in patients with poststroke fatigue: A double-blind, randomized, controlled preliminary study.** *J Ethnopharmacol.* 2016; **194**: 954–962.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Liu F, Li Y, Xu Y: **The intervention effect of wuling capsule on inflammatory reaction inpatients with post-stroke fatigue.** *Biomedical Research (India).* 2018; **29**(6): 1070–2.
[Publisher Full Text](#)
63. Bivard A, Lillicrap PT, Krishnamurthy V, *et al.*: **MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial.** *Stroke.* 2017; **48**(5): 1293–1298.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Bivard A, Lillicrap T, Krishnamurthy V, *et al.*: **Modafinil In Debilitating fatigue After Stroke (MIDAS): a randomized, doubleblind, placebo-controlled, cross-over trial.** *Eur Stroke J.* 2017; **2**(Suppl 1): 31.
[Publisher Full Text](#)
65. Lillicrap T, Krishnamurthy V, Attia J, *et al.*: **Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial.** *Trials.* 2016; **17**(1): 410.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Lillicrap TP, Levi CR, Holliday E, *et al.*: **Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial.** *Front Neurol.* 2018; **9**: 269.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Visser MM, Goodin P, Parsons MW, *et al.*: **Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue.** *Sci Rep.* 2019; **9**(1): 9660.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Visser MM, Maréchal B, Goodin P, *et al.*: **Predicting Modafinil-Treatment Response in Poststroke Fatigue Using Brain Morphometry and Functional Connectivity.** *Stroke.* 2019; **50**(3): 602–609.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. ACTRN12616001211459: **Effectiveness of cognitive behavior therapy for post-stroke fatigue and sleep disturbance: a pilot randomised controlled trial.** 2016.
[Reference Source](#)
70. Nguyen S, Wong D, McKay A, *et al.*: **Cognitive behavioural therapy for post-stroke fatigue and sleep disturbance: a pilot randomised controlled trial with blind assessment.** *Neuropsychol Rehabil.* 2019; **29**(5): 723–738.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. West A, Simonsen SA, Jennum P, *et al.*: **An exploratory investigation of the effect of naturalistic light on fatigue and subjective sleep quality in stroke patients admitted for rehabilitation: A randomized controlled trial.** *NeuroRehabilitation.* 2019; **45**(2): 187–200.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. West A, Simonsen SA, Jennum PJ, *et al.*: **The effects of circadian light on fatigue and subjective sleep quality in stroke patients admitted for rehabilitation.** *European Stroke Journal.* 2017; **2**(Suppl 1): 175.
73. West A, Simonsen SA, Sennels H, *et al.*: **The effect of naturalistic light on depressive mood, fatigue, subjective sleep quality and melatonin and cortisol blood levels in stroke patients admitted for rehabilitation.** *Neuropsychobiology.* 2016; **74**(4): 255.
74. Delva II: **Effectiveness of acetylsalicylic acid in correction of post-stroke fatigue during acute cerebrovascular events.** *Medical and Ecological Problems.* 2019; **23**(1–2): 8–12.
[Publisher Full Text](#)
75. Van Heest KNL, Mogush AR, Mathiowetz VG: **Effects of a One-to-One Fatigue Management Course for People With Chronic Conditions and Fatigue.** *Am J Occup Ther.* 2017; **71**(4): 7104100020p1–7104100020p9.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Wu S, Chalder T, Anderson KE, *et al.*: **Development of a psychological intervention for fatigue after stroke.** *PLoS One.* 2017; **12**(8): e0183286.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Blomgren C, Samuelsson H, Blomstrand C, *et al.*: **Long-term performance of instrumental activities of daily living in young and middle-aged stroke survivors-Impact of cognitive dysfunction, emotional problems and fatigue.** *PLoS One.* 2019; **14**(5): e0216822.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Chen K, Marsh EB: **Chronic post-stroke fatigue: It may no longer be about the stroke itself.** *Clin Neurol Neurosurg.* 2018; **174**: 192–197.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Choi-Kwon S, Ko M, Jun SE, *et al.*: **Post-Stroke Fatigue May Be Associated with the Promoter Region of a Monoamine Oxidase A Gene Polymorphism.** *Cerebrovasc Dis.* 2017; **43**(1–2): 54–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Douven E, Köhler S, Schievink SHJ, *et al.*: **Temporal Associations between Fatigue, Depression, and Apathy after Stroke: Results of the Cognition and Affect after Stroke, a Prospective Evaluation of Risks Study.** *Cerebrovasc Dis.* 2017; **44**(5–6): 330–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Drummond A, Hawkins L, Sprigg N, *et al.*: **The Nottingham Fatigue after Stroke (NotFAST) study: Factors Associated With Severity of Fatigue in Stroke Patients Without Depression.** *Clin Rehabil.* 2017; **31**(10): 1406–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Hawkins L, Drummond A: **Post stroke fatigue: a priority for stroke nursing?** *Br J Neurosci Nurs.* 2017; **13**(Sup2): S6.
[Publisher Full Text](#)
83. Hawkins L, Drummond A, Birks E, *et al.*: **The Nottingham Fatigue After Stroke study The frequency of fatigue and associated factors in stroke patients without depression...The 35th Scientific Meeting of the Physiotherapy Research Society 16 April 16, versity of Leicester, UK.** *International Journal of Therapy & Rehabilitation.* 2016; **23**(6): S270–1.
84. Hawkins L, Lincoln NB, Sprigg N, *et al.*: **The Nottingham Fatigue After Stroke (NotFAST) Study: Results From Follow-Up Six Months After Stroke.** *Top Stroke Rehabil.* 2017; **24**(8): 592–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Worthington E, Hawkins L, Lincoln N, *et al.*: **The day-to-day experiences of people with fatigue after stroke: Results from the Nottingham Fatigue After Stroke study.** *Int J Therapy & Rehabil.* 2017; **24**(10): 449–55.
[Publisher Full Text](#)
86. Ponchel A, Labreuche J, Bombois S, *et al.*: **Influence of Medication on Fatigue Six Months after Stroke.** *Stroke Res Treat.* 2016; **2016**: 2410921.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Bunevicius A: **Reader Response: Depressed TSH Level as a Predictor of Poststroke Fatigue in Patients With Acute Ischemic Stroke.** *Neurology.* 2019; **93**(12): 563–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Ganesh A, Galetta S: **Editors' note: Depressed TSH level as a predictor of poststroke fatigue in patients with acute ischemic stroke.** *Neurology.* 2019; **93**(12): 563.
[Publisher Full Text](#)
89. Wang J, Gu M, Sun W, *et al.*: **Author response: Depressed TSH level as a predictor of poststroke fatigue in patients with acute ischemic stroke.** *Neurology.* 2020.
[Reference Source](#)
90. Wang J, Li F, Xiao L, *et al.*: **Depressed TSH level as a predictor of poststroke fatigue in patients with acute ischemic stroke.** *Neurology.* 2018; **91**(21): e1971–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Mahon S, Theadom A, Barker-Collo S, *et al.*: **The Contribution of Vascular Risk Factors in Prevalence of Fatigue Four Years Following Stroke: Results from a Population-Based Study.** *J Stroke Cerebrovasc Dis.* 2018; **27**(8): 2192–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Choi-Kwon S, Choi SH, Suh M, *et al.*: **Musculoskeletal and central pain at 1 year post-stroke: associated factors and impact on quality of life.** *Acta Neurol Scand.* 2017; **135**(4): 419–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Kuppuswamy A, Clark E, Rothwell J, *et al.*: **Limb Heaviness: A Perceptual Phenomenon Associated With Poststroke Fatigue?** *Neurorehabil Neural Repair.* 2016; **30**(4): 360–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Elf M, Eriksson G, Johansson S, *et al.*: **Self-Reported Fatigue and Associated Factors Six Years after Stroke.** *PLoS One.* 2016; **11**(8): e0161942.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Lau CG, Tang WK, Liu XX, *et al.*: **Neuroticism and Fatigue 3 Months After Ischemic Stroke: A Cross-Sectional Study.** *Arch Phys Med Rehabil.* 2017; **98**(4): 716–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. MacIntosh BJ, Edwards JD, Kang M, *et al.*: **Post-stroke Fatigue and Depressive Symptoms Are Differentially Related to Mobility and Cognitive Performance.** *Front Aging Neurosci.* 2017; **9**: 343.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. van Rijsbergen MWA, Mark RE, Kop WJ, *et al.*: **Psychological factors and subjective cognitive complaints after stroke: Beyond depression and anxiety.**

- Neuropsychol Rehabil.* 2019; **29**(10): 1671–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Braun LT, Grady KL, Kutner JS, *et al.*: **Palliative Care and Cardiovascular Disease and Stroke: A Policy Statement From the American Heart Association/ American Stroke Association.** *Circulation.* 2016; **134**(11): e198–225.
[PubMed Abstract](#) | [Publisher Full Text](#)
 99. Peberdy MA, Gluck JA, Ornato JP, *et al.*: **Cardiopulmonary Resuscitation in Adults and Children With Mechanical Circulatory Support: A Scientific Statement From the American Heart Association.** *Circulation.* 2017; **135**(24): e1115–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 100. Management of Stroke Rehabilitation Work Group, Office of Quality Safety and Value, Office of Evidence Based Practice: **VA/DoD Clinical Practice Guideline for the Management of Stroke Rehabilitation: Department of Veterans Affairs and Department of Defense.** 2019.
[Reference Source](#)
 101. Winstein CJ, Stein J, Arena R, *et al.*: **Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.** *Stroke.* 2016; **47**(6): e98–e169.
[PubMed Abstract](#) | [Publisher Full Text](#)
 102. Zhang J, Gong Y, Zhao Y, *et al.*: **Post-stroke medication adherence and persistence rates: a meta-analysis of observational studies.** *J Neurol.* 2019.
[PubMed Abstract](#) | [Publisher Full Text](#)
 103. ACTRN12618000602224: **Modafinil In Debilitating Fatigue After Stroke 2 (MIDAS 2).** 2018.
 104. Drummond A: **NotFAST2 - Nottingham Fatigue study: developing a fatigue intervention.** Stroke Association and University of Nottingham. 2019.
[Reference Source](#)
 105. Chen Y, Yang K, Marušić A, *et al.*: **A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement.** *Ann Intern Med.* 2017; **166**(2): 128–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 106. Brouwers MC, Kerkvliet K, Spithoff K, *et al.*: **The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines.** *BMJ.* 2016; **352**: i1152.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 107. Vernooij RW, Alonso-Coello P, Brouwers M, *et al.*: **Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp).** *PLoS Med.* 2017; **14**(1): e1002207.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 108. Abildstrom SZ, Torp-Pedersen C, Madsen M: **Register-based studies of cardiovascular disease.** *Scand J Public Health.* 2011; **39**(7 Suppl): 165–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 109. Jones CW, Keil LG, Holland WC, *et al.*: **Comparison of registered and published outcomes in randomized controlled trials: a systematic review.** *BMC Med.* 2015; **13**: 282.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 110. Pöttgen J, Moss-Morris R, Wendebourg JM, *et al.*: **Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.** *J Neurol Neurosurg Psychiatry.* 2018; **89**(9): 970–976.
[PubMed Abstract](#) | [Publisher Full Text](#)
 111. Mathieu S, Boutron I, Moher D, *et al.*: **Comparison of registered and published primary outcomes in randomized controlled trials.** *JAMA.* 2009; **302**(9): 977–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 112. Shokraneh F, Aali G: **Post-Stroke Fatigue: A Scoping Review.** 2020.
<http://www.doi.org/10.17605/OSF.IO/XJKCS>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 02 September 2020

<https://doi.org/10.5256/f1000research.27636.r70217>

© 2020 Persson C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Carina U. Persson

Department of Clinical Neuroscience, Rehabilitation Medicine, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

The authors perfectly solved or clarified all the issues that I raised. I would like to congratulate them on this interesting paper.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 04 May 2020

<https://doi.org/10.5256/f1000research.25259.r62109>

© 2020 Hancock N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nicola Hancock

School of Health Sciences, University of East Anglia, Norwich, UK

Thank you for the invitation to review this interesting scoping review, focussing on an important area of current research highly relevant to multiple aspects of life after stroke- that of Post-Stroke Fatigue, PSF.

The current review updates the work of Hinkle *et al.* 2016, and the rationale for doing so is clearly stated by the authorship team. That the review here generated a further 24 studies (and six sets of guidelines including PSF) since 2016 further demonstrates the growing impetus of work in this area. The objective stated is rather non-specific, but this is acceptable in such a scoping review that serves as a summary of recent evidence. It is unsurprising that this review concludes that further research in this area is required, and the authors make relevant suggestions as to the characteristics of future research that are clearly based on the findings of this review.

The review is clearly written, and the methods used and ensuing findings have been reported with transparency and considerable attention to detail. Search strategies are available via an embedded link. This paper makes a very useful contribution and provides a foundation for further work.

The following minor comments and suggestions may be of use to the authors:

- The use of the word 'following' in the opening two section headings of the methods might be worth reconsidering, readability of this phrase in a title is challenging (page 3).
- In Figure 1, suggest clarifying '34 not new/covered'- does this mean 34 records removed as covered in the previous review? (page 4).
- Section on data extracted from clinical practice guidelines, please clarify 'study name and year'- does this refer to the name and year of the guidelines or the included studies from which the guidelines was written? (page 5).
- Was any specific tool used to assess risk of bias in the non-randomised studies? If so, this should be stated in the methods text. If not, some justification would be helpful.
- In table 3, the final column is not entirely clear- is this mean time after stroke onset for included participants? Simple clarification in the column heading or legend would address this (page 7/8).
- Suggest rephrasing 'probably the most effective interventions' to deliver a clearer message here (page 9).
- In the discussion, the section on online platforms is somewhat unexpected- possible delivery via online mechanisms does not seem to have arisen prior to this point, though I apologise if I have missed this. Perhaps a line to place this paragraph in context might help the interpretation here? (page 10).
- As the authors focus on possible reasons for the use of the Fatigue Severity Score (FSS) in one section of the discussion, it might be helpful to include a line about the validity/reliability of this measure at this point.
- There are a few very minor typographical and grammatical errors.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Not applicable

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Stroke rehabilitation

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 23 Jun 2020

Ghazaleh Aali, University of Nottingham, Nottingham, UK

We thank the expert reviewer for spending time on our review and for providing helpful comments. We have made amendments to the manuscript based on these comments.

Comment: The use of the word 'following' in the opening two section headings of the methods might be worth reconsidering, readability of this phrase in a title is challenging (page 3).

Reply: Thank you. We have now changed these to 'Methods from an existing review' and 'Scoping review methods'.

Comment: In Figure 1, suggest clarifying '34 not new/covered'- does these mean 34 records removed as covered in the previous review (page 4)?

Reply: We have now clarified this in the text. We excluded studies that had been covered in the previous review. We also excluded the new studies that were not covered in the previous review if they repeated the findings reported in the previous reviews. We included new studies that were repeating findings from the previous review if they had a larger sample size or a new factor or intervention so were adding to the existing knowledge. This is compatible with the 'scoping' element of this review.

Comment: Section on data extracted from clinical practice guidelines, please clarify 'study name and year'- does this refer to the name and year of the guidelines or the included studies from which the guidelines was written (page 5).

Reply: The 'Citation' column refers to the reference publication and publication date of the guideline.

Comment: Was any specific tool used to assess risk of bias in the non-randomised studies? If so, this should be stated in the methods text. If not, some justification would be helpful.

Reply: Assessing risk of bias is not usually a feature of scoping reviews. However, because of availability of the automation tool (i.e. RobotReviewer) for RCTs and to provide additional

training to two PhD students who were involved in this review, we added risk of bias assessment only for the RCTs. We did not assess non-RCTs for risk of bias because our resources were limited. We have now addressed this in the text: "Because of the 'scoping' nature of this review and lack of time and resources, we did not assess the risk of bias for non-RCTs."

Comment: In Table 3, the final column is not entirely clear- is this mean time after stroke onset for included participants? Simple clarification in the column heading or legend would address this (page 7/8).

Reply: It is both. Because of the lack of standards in reporting these data, some studies reported time period after stroke and some reported only mean and standard deviation. We have now detailed this under the table.

Comment: Suggest rephrasing 'probably the most effective interventions' to deliver a clearer message here (page 9).

Reply: We have changed 'the most effective' to 'the future'.

Comments: In the discussion, the section on online platforms is somewhat unexpected- possible delivery via online mechanisms does not seem to have arisen prior to this point, though I apologise if I have missed this. Perhaps a line to place this paragraph in context might help the interpretation here (page 10)?

Reply: Thank you. In the second paragraph of the Results we note that the delivery was mostly face-to-face and individually rather than online.

Comment: As the authors focus on possible reasons for the use of the Fatigue Severity Score (FSS) in one section of the discussion, it might be helpful to include a line about the validity/reliability of this measure at this point.

Reply: We have added a sentence about validity/reliability: "Bearing in mind that both these PSF measurement scales are valid and reliable...". We therefore tried to raise the other 'possible' reasons for the frequent use of this specific scale in this field.

Comment: There are a few very minor typographical and grammatical errors.

Reply: Thank you. We have now addressed these and apologise for overlooking these.

Competing Interests: None to declare.

Reviewer Report 22 April 2020

<https://doi.org/10.5256/f1000research.25259.r62111>

© 2020 Persson C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Carina U. Persson

Department of Clinical Neuroscience, Rehabilitation Medicine, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

I found this scoping review very exciting to read since it addresses a very important issue that needs to be managed daily in post-stroke rehabilitation. I believe that the interest in post-stroke fatigue is great from both researchers and clinically active colleagues. I am positive to and welcome this type of “game-changer” by a transparent scientific publishing.

The title identifies the manuscript as a scoping review and reflects the population (individuals post-stroke) and the construct (post-stroke fatigue). The abstract is presented with a clear structure, including background, methods, results and conclusion, of which all parts relate to the aim of the study. The rationale for the review is described; there is insufficient evidence of the efficacy of the interventions related to post-stroke fatigue in conducted trials and more robust research with adequate sample sizes is required. In addition, it was time to make an update. The objective is well described, to identify and summarise the most recent research related to post-stroke fatigue in order to update the evidence base. The update covers new research studies between 1st March 2016 and 19th January 2020. The search strategies for the databases are reported in a separate link (*Extended data*). In the results, data related to the objective of the study is presented with a clear structure in six tables. These tables include characteristics of, and summary of the findings from, the included interventional and observational studies, risk of bias and a summary of included guidelines. Due to the heterogeneity of studies, no meta-analysis for fatigue outcomes was performed. The interventional studies were limited by either having high risk of bias or small sample size. Consequently, transferring the research findings to practice was hard.

The current manuscript is well written and easy to follow. It is clear that you have put in a lot of effort and made a great job. Even so, I have following minor comments/suggestions that could possibly improve your article:

Method:

- As written, I am uncertain about limitations to language. According to the manuscript, there were no limitations to language. However, in the *Extended data*, English language seems to be a limitation in the search strategies. Please, clarify so there is no doubt about this.
- Figure 1: Please, consider clarifying the number of excluded reports per each specified criterion regarding the 473 excluded reports; no clarification (in numbers) has been made for them as for the 86-excluded full-text reports.
- Figure 1: Please, give the readers more information about the nine additional sources. Which was your strategy, how did you find them? Did all arrived from the other articles' reference lists?

Results:

- Are MIDAS (presented in Table 1), and ARCOS-IV and LAS-1 (presented in Table 3) examples of studies not yet published?
- (In Table 1, the fourth column, there is space available (two rows are already used) for you to write “Number of participants” or “No.” instead of using the symbol “#”.)

- Table 2: I like the use of different colours, and red and green are instantaneous to understand. However, in color blindness, the most common difficulty is to distinguish between red and green. Perhaps you can choose another colour combination. In the online version of Robot Reviewer report, I think that the table Risk of bias has a more easy to read layout than Table 2 in the main manuscript.
- (Table 3: Consider using "Number" or "Number of" or "No." or "No. of" instead of "#" in the third and the fifth column?)
- Table 3, sixth column, "Stroke type": Please, review the use of "/". Should you use "and", ",", or delete the "/" somewhere? Regarding Kuppuswamy and NotFAST: "First", but which stroke type?
- (Table 4, fourth column: I suggest you to use "Post-stroke fatigue finding" instead of the use of the abbreviation "PSF finding". Avoiding unnecessary abbreviations makes reading easier.)
- (In Table 5, consider if you should specify "Finding" to "Post-stroke fatigue finding" in the light blue heading (in line with the selected sub-heading in Table 4).)
- In the data commentary related to Table 6, you state that the Canadian guideline was the only one with comprehensive recommendations on post-stroke fatigue. In Table 6, under the heading "Recommendation" the reader is referred to page 15-16 of the guideline. I suggest that you present vital parts of the content in Table 6, in addition to this reference.
- I lack information on age and gender of the patients in the different studies from which the review is based. Is it possible to add this information?
- Is it possible to give the reader even more specific information on which quantitative measures the post-stroke fatigue findings are based? (Although the level of significance is arbitrary set and statistically significance results does not need to be clinically meaningful for the patients.)

Discussion:

- I suggest a sentence about time-dependent concerns regarding the construct (post-stroke fatigue) in the research studies conducted years after stroke and its potential significance for validity.
- International recommendations regarding outcome measures related to, and time points for measuring, post-stroke fatigue in research studies on recovery after stroke would probably reduce the heterogeneity of studies and facilitate further summaries and updates. You could possibly include that post-stroke fatigue might be an issue for future Stroke Recovery and Rehabilitation Roundtable (SRRR) work.
- You have a separate paragraph regarding limitations. Have you thought about including a sentence related to strengths of your study, in a paragraph in close proximity to "Limitations"?

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Not applicable

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 23 Jun 2020

Ghazaleh Aali, University of Nottingham, Nottingham, UK

We are grateful to the expert reviewer for their interest in the topic and for spending time in reviewing this manuscript. We value their positive and thorough comments and have revised the manuscript accordingly.

Method

Comment: As written, I am uncertain about limitations to language. According to the manuscript, there were no limitations to language. However, in the extended data, English language seems to be a limitation in the search strategies. Please, clarify so there is no doubt about this.

Reply: Thank you for this comment. We initially intended to have no language restrictions but, as we followed the methods from an existing scoping review, we needed to apply a language limitation. This has now been corrected to: "We ran a search to include studies in English language only...".

Comment: Figure 1: Please, consider clarifying the number of excluded reports per each specified criterion regarding the 473 excluded reports; no clarification (in numbers) has been made for them as for the 86-excluded full-text reports.

Reply: We followed the PRISMA reported guideline and flow diagram which does not specify recording or reporting detailed reasons for exclusion at the Title/Abstract Screening step (Liberati et al. 2009; DOI 10.1136/bmj.b2700); however, as it is mandatory to report the reasons for exclusion in the Full Text Screening step, we have done this.

Comment: Figure 1: Please, give the readers more information about the nine additional sources. Which was your strategy, how did you find them? Did all arrive from the other articles' reference lists?

Reply: We have now included this statement under the Selection of studies section: "we also

investigated the reference lists of the relevant studies to identify additional relevant studies".

Results

Comment: Are MIDAS (presented in Table 1), and ARCOS-IV and LAS-1 (presented in Table 3) examples of studies not yet published?

Reply: No. These studies were completed and have reported their results, so they met our eligibility criteria. If a study was 'ongoing' at the time of our review, we did not report them in the table because "Ongoing studies or protocols with no results" was one of our exclusion criteria. If a study had no specific name, we used the last name of the first author and the year of publication as the study name in the tables.

Comment: In Table 1, the fourth column, there is space available (two rows are already used) for you to write "Number of participants" or "No." instead of using the symbol "#".

Reply: We have corrected this now to "No. of".

Comment: Table 2: I like the use of different colours, and red and green are instantaneous to understand. However, in colour blindness, the most common difficulty is to distinguish between red and green. Perhaps you can choose another colour combination. In the online version of Robot Reviewer report, I think that the table Risk of bias has a more easy to read layout than Table 2 in the main manuscript.

Reply: We followed Cochrane's Risk of Bias tool and therefore also followed their reporting method. However we recognise that some of our readers might be colour-blind and so we are using plus signs and question marks in addition to the colour coding. We have also now changed the colours from red/green to grey/white.

Comment: Table 3: Consider using "Number" or "Number of" or "No." or "No. of" instead of "#" in the third and the fifth column?

Reply: We have corrected these to "No. of".

Comment: Table 3, sixth column, "Stroke type": Please, review the use of "/". Should you use "and", ",", or delete the "/" somewhere? Regarding Kuppaswamy and NotFAST: "First", but which stroke type?

Reply: We replaced "/" with ", ". We used type of stroke as reported in the studies. Thus, although 'First' does not refer to a specific stroke type, this was what was reported and therefore what we presented under 'type'. Since this is a scoping review, we did not contact specific researchers to clarify these details.

Comment: Table 4, fourth column: I suggest you to use "Post-stroke fatigue finding" instead of the use of the abbreviation "PSF finding". Avoiding unnecessary abbreviations makes reading easier.

Reply: We have now corrected this to 'post-stroke fatigue'.

Comment: In Table 5, consider if you should specify "Finding" to "Post-stroke fatigue finding" in the light blue heading (in line with the selected sub-heading in Table 4).

Reply: We have now added 'post-stroke fatigue'.

Comment: In the data commentary related to Table 6, you state that the Canadian guideline was the only one with comprehensive recommendations on post-stroke fatigue. In Table 6, under the heading "Recommendation" the reader is referred to page 15-16 of the guideline. I suggest that you present vital parts of the content in Table 6, in addition to this reference.

Reply: We did consider this approach initially. However, for the following reasons we decided not to report the text for this guideline: 1. there are two pages of content that could be paraphrased and summarized into the table but because of the volume of the content (even after summarizing and paraphrasing) it would require official copyright permission from the publisher of the guideline. Aside from the process of obtaining such permission, this will require payment to the publisher which is not included within our grant. 2. We found the content of these two pages relevant, well-written, and important, and we have consequently intentionally referred the reader to this source, rather than paraphrasing and losing important detail.

Comment: I lack information on age and gender of the patients in the different studies from which the review is based. Is it possible to add this information?

Reply: If it is not reported in our review, it means that this information was missing from the primary study. Since this is a scoping review, we did not consider contacting each researcher separately. However, we have highlighted the fact that even very basic but important demographic information has not been reported by researchers of the primary studies. Not including key demographic information is an important issue to highlight, because it needs to be addressed in future studies

Comment: Is it possible to give the reader even more specific information on which quantitative measures the post-stroke fatigue findings are based? (Although the level of significance is arbitrary set and statistically significance results does not need to be clinically meaningful for the patients.

Reply: Reporting/calculating effect sizes is not routine practice or part of reporting guidelines for conducting scoping reviews. However, we thought this revision could add to the value of the interventional studies so we reported these statistics in Table 4. Since this is not a systematic review, we did not consider contacting the researchers for complete information and we did not calculate or combine the effect sizes. Instead we reported the statistics as they were reported in the original studies.

Discussion

Comment: I suggest a sentence about time-dependent concerns regarding the construct (post-stroke fatigue) in the research studies conducted years after stroke and its potential significance for validity.

Reply:

Thank you. We have added the following: "One issue worth considering is whether the construct of PSF holds for fatigue experienced in research participants recruited years after their stroke, and whether this fatigue is a function of other issues. Future systematic reviews could address this issue by conducting sensitivity analyses comparing studies that include participants many years after their stroke with those including participants immediately after their stroke."

Comment: International recommendations regarding outcome measures related to, and time points for measuring, post-stroke fatigue in research studies on recovery after stroke would probably reduce the heterogeneity of studies and facilitate further summaries and updates. You could possibly include that post-stroke fatigue might be an issue for future Stroke Recovery and Rehabilitation Roundtable (SRRR) work.

Reply:

Thank you for this suggestion. We have made a comment about this being an important area for future research but do not want to identify an individual group or organization to take this forward. We added: "In addition, harmonisation of studies requires standard international guidelines regarding outcome measurements and time points for measuring PSF in a standard way to create homogenous and collective body of evidence."

Comment: You have a separate paragraph regarding limitations. Have you thought about including a sentence related to strengths of your study, in a paragraph in close proximity to "Limitations"?

Reply: Thank you for this comment. We have changed the heading to 'Limitations and Strengths' and added three strengths of the review in this section: A. Public and open sharing of our methods so that anyone can update our review, B. Utilizing automation tools such as Rayyan and RobotReviewer to save time and resources and C. The fact that this was A multi-disciplinary review team.

Competing Interests: None to declare.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research